These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24338217)

  • 21. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
    Marks EI; Matera R; Olszewski AJ; Yakirevich E; El-Deiry WS; Safran H; Carneiro BA
    Am J Clin Oncol; 2021 Feb; 44(2):68-73. PubMed ID: 33298767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
    Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
    Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
    Clarke S; Burge M; Cordwell C; Gibbs P; Reece W; Tebbutt N
    BMC Cancer; 2013 Mar; 13():120. PubMed ID: 23497305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of C677T and A1298C
    Ramos-Esquivel A; Chinchilla R; Valle M
    Anticancer Res; 2020 Aug; 40(8):4263-4270. PubMed ID: 32727753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.